Muse Related Published Studies
Well-designed clinical trials related to Muse (Alprostadil)
Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. [2007.10]
Effects of pentoxifylline and alprostadil on ocular hemodynamics in healthy humans. [2007.02]
[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)] [2007]
An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. [2006.08]
Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy. [2006.03]
[Reevaluation of protective effects of alprostadil on hepatic function in patients undergoing hepatectomy] [2005.09]
Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. [2005.01]
Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1). [2004.08]
Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study. [2004.02]
Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. [2004]
Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. [2003.10]
Intravenous alprostadil, an analog of prostaglandin E1, prevents thiamylal-fentanyl-induced bronchoconstriction in humans. [2003.08]
The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. [2003.02]
Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction. [2002.12]
Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. [2002.12]
A synthetic prostaglandin E1 analog, alprostadil alfadex, relaxes sphincter of Oddi in humans. [2002.01]
A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. [2001.02]
Effect of intravenous iloprost and alprostadil (PGE1) on peripheral resistance during femoro-distal reconstructions. [2000.12]
Optimizing the therapeutic approach of transurethral alprostadil. [2000.07]
Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. [2000.01]
Intracavernosal versus intraurethral alprostadil: a prospective randomized study. [1999.05]
The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. [1998.12]
Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. [1998.06]
Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. [1998.05]
Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. [1998.01]
Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators. [1997.11]
Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators. [1997.11]
Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. [1997.10]
Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. [1997.01.02]
A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. [1996.12]
A cost analysis of alprostadil in liver transplantation. [1996.06]
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. [1996.04.04]
Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. [1996.04]
Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction. [1996]
A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group. [1995.11]
Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. [1995.09]
An alprostadil analogue and human gastric secretion. A double-blind placebo-controlled study of the effects of a capsule and tablet formulation. [1989.07]
An alprostadil analogue and human gastric secretion. A double-blind placebo-controlled study of the effects of a tablet and lyovial formulation. [1987.08]
Well-designed clinical trials possibly related to Muse (Alprostadil)
Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. [2008.06]
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. [2008.04]
Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). [2008.01]
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. [2008.01]
Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. [2007.10]
Efficacy and safety of misoprostol in induction of labour in a Nigerian tertiary hospital. [2007.07]
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. [2007.06.01]
Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. [2007.05]
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. [2007.02]
Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. [2006.12]
Intraamniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy. [2006.06.01]
The effects of prostaglandin E-1 in patients with intermittent claudication. [2006.06]
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. [2006.05]
Prostaglandin E1 attenuates impairment of cellular immunity after cardiopulmonary bypass. [2006.04]
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. [2006.04]
Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. [2006.03.01]
Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. [2006.03]
An investigation of misoprostol in the promotion of wound healing. [2006]
Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. [2005.12]
Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. [2005.12]
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. [2005.12]
Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. [2005.08]
Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. [2005.08]
Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss. [2005.07]
Priming effect of misoprostol on estrogen pretreated cervix in postmenopausal women. [2005.07]
A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. [2005.07]
Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. [2005.06]
Effect of glutamine on water and sodium absorption in human jejunum at baseline and during PGE1-induced secretion. [2005.06]
Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1. [2005.05]
Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy. [2005.03]
Second trimester abortion using isosorbide mononitrate in addition to gemeprost compared with gemeprost alone: a double-blind randomized, placebo-controlled multicenter trial. [2005.03]
Medical versus surgical abortion: comparing satisfaction and potential confounders in a partly randomized study. [2005.03]
Saturation with oxygen for ductal dependent congenital heart diseases before and after the prostaglandin therapy. [2005.02]
Medical versus surgical abortion efficacy, complications and leave of absence compared in a partly randomized study. [2004.11]
Prostaglandin E1 versus lumbar sympathectomy in the treatment of peripheral arterial occlusive disease: randomised study of 86 patients. [2004.08]
Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial. [2004.08]
Effect of prostaglandin E1 on inflammatory responses and gas exchange in patients undergoing surgery for oesophageal cancer. [2004.08]
[Prostaglandin E1 reduces reperfusion injury of myocardium by inhibiting cytokines production during cardiac surgery] [2004.07]
Urinary nitric oxide metabolite changes in spontaneous and induced onset active labor. [2004.07]
Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. [2004.06]
Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia. [2004.06]
Effects of isoflurane-induced and prostaglandin E(1)-induced hypotension on cytokine responses to oral and maxillofacial surgery. [2004.05]
The effect of prostaglandin E1 on nailfold capillary blood pressure and red blood cell velocity in humans. [2004]
Perioperative prostaglandin E1 treatment for the prevention of postoperative complications after esophagectomy: a randomized clinical trial. [2004]
A prospective randomized controlled trial that compared misoprostol, Foley catheter, and combination misoprostol-Foley catheter for labor induction. [2003.10]
The MisoPROM study: a multicenter randomized comparison of oral misoprostol and oxytocin for premature rupture of membranes at term. [2003.10]
Effect of prostaglandin E1 on contrast enhanced CT of the liver: statistical analysis during arterial portography. [2003.08]
Aminophylline for the prevention of apnea during prostaglandin E1 infusion. [2003.07]
Effect of linoleic acid and gamma-linolenic acid on tear production, tear clearance and on the ocular surface after photorefractive keratectomy. [2003.07]
Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease. [2003.06]
[Effect of prostaglandin E1 infusion during and after total hip arthroplasty under hypotensive anesthesia on postoperative renal function and urine volume] [2003.06]
[Efficacy and safety of PGE1 cream in the treatment of erectile dysfunction] [2003.04]
Gemeprost versus misoprostol for cervical priming before first-trimester abortion: a randomized controlled trial. [2003.04]
Prostaglandin E1 but not corticosteroid increases nerve root blood flow velocity after lumbar diskectomy in surgical patients. [2003.04]
[Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs] [2002.12]
A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. [2002.11]
Predictive value of blood flow in the gastric tube in anastomotic insufficiency after thoracic esophagectomy. [2002.11]
Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a double-blinded clinical study. [2002.09]
Pilot safety study of liposomal prostaglandin (PGE1) in respiratory exacerbations in cystic fibrosis. [2002.06]
The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. [2002.06]
[Effect of prostaglandin E1 infusion during and after total hip arthroplasty under hypotensive anesthesia on postoperative liver function and hemorrhage] [2002.04]
Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. [2002.02.15]
[The effects of prostaglandin E1 on systemic and cerebral oxygenation before and during cardiopulmonary bypass] [2002.02]
|
